Enhancing effect of the liver extract and flavin adenin dinucleotide mixture on anti-viral efficacy of interferon in patients with chronic hepatitis C

Hidetsugu Saito, Hirotoshi Ebinuma, Shinichiro Tada, Satoshi Tsunematsu, Kazuhiro Atsukawa, Tetsuya Masuda, Masaharu Tsuchiya, Hiromasa Ishii

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A combined preparation of liver extract and flavin adenin dinucleotide (FAD) (Adelavin®) has been widely used in patients with chronic liver diseases in Japan. One milliliter of this agent contains 15 μl of phenol-soluble phase of liver nucleic acid fraction and 10 mg of FAD. To examine the advantages of using this preparation in the elimination of hepatitis C virus (HCV) from patients with chronic hepatitis (CH)-C receiving interferon (IFN), 2 ml of this preparation was intravenously (n = 9) or intramuscularly (n = 8) administered daily for 5 days before 6 million units of IFN-α was intramuscularly injected once. Before and 48 hours after the injection of IFN, serum ALT, 2'5'-oligoadenylate synthetase (2'5-AS) activity, and HCV RNA levels were measured. The daily administration of this preparation alone for 5 days did not significantly change serum ALT, 2'5-AS activities, and HCV RNA levels. The 2'5-AS activities were significantly increased by IFN after the intravenous injection of this preparation (p < 0.01), while an injection of IFN alone of this dose did not change its activities (n = 10). HCV RNA levels were significantly decreased by IFN only after the administration of the preparation (intramuscular, p < 0.01; intravenous, p < 0.01). The effect of intravenous injection of this preparation was also elicited in patients with HCV genotype D and with HCV more than 105 copies/ml. These results suggest that this preparation may enhance the 2'5-AS production by IFN as a result of the increase in mitochondrial adenosin triphosphate production and may be a potent agent to enhance the anti-viral efficacy of IFN in patients with CH-C.

Original languageEnglish
Pages (from-to)48-53
Number of pages6
JournalKeio Journal of Medicine
Volume45
Issue number1
Publication statusPublished - 1996 Mar

Fingerprint

Liver Extracts
Chronic Hepatitis C
Interferons
Hepacivirus
Ligases
RNA
Intravenous Injections
Injections
4,6-dinitro-o-cresol
Phenol
Serum
Nucleic Acids
Liver Diseases
Japan
Chronic Disease
Genotype
2',5'-oligoadenylate
Liver

Keywords

  • chronic hepatitis C
  • flavin adenin dinucleotide
  • interferon
  • liver extract

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Enhancing effect of the liver extract and flavin adenin dinucleotide mixture on anti-viral efficacy of interferon in patients with chronic hepatitis C. / Saito, Hidetsugu; Ebinuma, Hirotoshi; Tada, Shinichiro; Tsunematsu, Satoshi; Atsukawa, Kazuhiro; Masuda, Tetsuya; Tsuchiya, Masaharu; Ishii, Hiromasa.

In: Keio Journal of Medicine, Vol. 45, No. 1, 03.1996, p. 48-53.

Research output: Contribution to journalArticle

Saito, H, Ebinuma, H, Tada, S, Tsunematsu, S, Atsukawa, K, Masuda, T, Tsuchiya, M & Ishii, H 1996, 'Enhancing effect of the liver extract and flavin adenin dinucleotide mixture on anti-viral efficacy of interferon in patients with chronic hepatitis C', Keio Journal of Medicine, vol. 45, no. 1, pp. 48-53.
Saito, Hidetsugu ; Ebinuma, Hirotoshi ; Tada, Shinichiro ; Tsunematsu, Satoshi ; Atsukawa, Kazuhiro ; Masuda, Tetsuya ; Tsuchiya, Masaharu ; Ishii, Hiromasa. / Enhancing effect of the liver extract and flavin adenin dinucleotide mixture on anti-viral efficacy of interferon in patients with chronic hepatitis C. In: Keio Journal of Medicine. 1996 ; Vol. 45, No. 1. pp. 48-53.
@article{cff0577e95e34de694f15d9911d471b8,
title = "Enhancing effect of the liver extract and flavin adenin dinucleotide mixture on anti-viral efficacy of interferon in patients with chronic hepatitis C",
abstract = "A combined preparation of liver extract and flavin adenin dinucleotide (FAD) (Adelavin{\circledR}) has been widely used in patients with chronic liver diseases in Japan. One milliliter of this agent contains 15 μl of phenol-soluble phase of liver nucleic acid fraction and 10 mg of FAD. To examine the advantages of using this preparation in the elimination of hepatitis C virus (HCV) from patients with chronic hepatitis (CH)-C receiving interferon (IFN), 2 ml of this preparation was intravenously (n = 9) or intramuscularly (n = 8) administered daily for 5 days before 6 million units of IFN-α was intramuscularly injected once. Before and 48 hours after the injection of IFN, serum ALT, 2'5'-oligoadenylate synthetase (2'5-AS) activity, and HCV RNA levels were measured. The daily administration of this preparation alone for 5 days did not significantly change serum ALT, 2'5-AS activities, and HCV RNA levels. The 2'5-AS activities were significantly increased by IFN after the intravenous injection of this preparation (p < 0.01), while an injection of IFN alone of this dose did not change its activities (n = 10). HCV RNA levels were significantly decreased by IFN only after the administration of the preparation (intramuscular, p < 0.01; intravenous, p < 0.01). The effect of intravenous injection of this preparation was also elicited in patients with HCV genotype D and with HCV more than 105 copies/ml. These results suggest that this preparation may enhance the 2'5-AS production by IFN as a result of the increase in mitochondrial adenosin triphosphate production and may be a potent agent to enhance the anti-viral efficacy of IFN in patients with CH-C.",
keywords = "chronic hepatitis C, flavin adenin dinucleotide, interferon, liver extract",
author = "Hidetsugu Saito and Hirotoshi Ebinuma and Shinichiro Tada and Satoshi Tsunematsu and Kazuhiro Atsukawa and Tetsuya Masuda and Masaharu Tsuchiya and Hiromasa Ishii",
year = "1996",
month = "3",
language = "English",
volume = "45",
pages = "48--53",
journal = "Keio Journal of Medicine",
issn = "0022-9717",
publisher = "Keio University School of Medicine",
number = "1",

}

TY - JOUR

T1 - Enhancing effect of the liver extract and flavin adenin dinucleotide mixture on anti-viral efficacy of interferon in patients with chronic hepatitis C

AU - Saito, Hidetsugu

AU - Ebinuma, Hirotoshi

AU - Tada, Shinichiro

AU - Tsunematsu, Satoshi

AU - Atsukawa, Kazuhiro

AU - Masuda, Tetsuya

AU - Tsuchiya, Masaharu

AU - Ishii, Hiromasa

PY - 1996/3

Y1 - 1996/3

N2 - A combined preparation of liver extract and flavin adenin dinucleotide (FAD) (Adelavin®) has been widely used in patients with chronic liver diseases in Japan. One milliliter of this agent contains 15 μl of phenol-soluble phase of liver nucleic acid fraction and 10 mg of FAD. To examine the advantages of using this preparation in the elimination of hepatitis C virus (HCV) from patients with chronic hepatitis (CH)-C receiving interferon (IFN), 2 ml of this preparation was intravenously (n = 9) or intramuscularly (n = 8) administered daily for 5 days before 6 million units of IFN-α was intramuscularly injected once. Before and 48 hours after the injection of IFN, serum ALT, 2'5'-oligoadenylate synthetase (2'5-AS) activity, and HCV RNA levels were measured. The daily administration of this preparation alone for 5 days did not significantly change serum ALT, 2'5-AS activities, and HCV RNA levels. The 2'5-AS activities were significantly increased by IFN after the intravenous injection of this preparation (p < 0.01), while an injection of IFN alone of this dose did not change its activities (n = 10). HCV RNA levels were significantly decreased by IFN only after the administration of the preparation (intramuscular, p < 0.01; intravenous, p < 0.01). The effect of intravenous injection of this preparation was also elicited in patients with HCV genotype D and with HCV more than 105 copies/ml. These results suggest that this preparation may enhance the 2'5-AS production by IFN as a result of the increase in mitochondrial adenosin triphosphate production and may be a potent agent to enhance the anti-viral efficacy of IFN in patients with CH-C.

AB - A combined preparation of liver extract and flavin adenin dinucleotide (FAD) (Adelavin®) has been widely used in patients with chronic liver diseases in Japan. One milliliter of this agent contains 15 μl of phenol-soluble phase of liver nucleic acid fraction and 10 mg of FAD. To examine the advantages of using this preparation in the elimination of hepatitis C virus (HCV) from patients with chronic hepatitis (CH)-C receiving interferon (IFN), 2 ml of this preparation was intravenously (n = 9) or intramuscularly (n = 8) administered daily for 5 days before 6 million units of IFN-α was intramuscularly injected once. Before and 48 hours after the injection of IFN, serum ALT, 2'5'-oligoadenylate synthetase (2'5-AS) activity, and HCV RNA levels were measured. The daily administration of this preparation alone for 5 days did not significantly change serum ALT, 2'5-AS activities, and HCV RNA levels. The 2'5-AS activities were significantly increased by IFN after the intravenous injection of this preparation (p < 0.01), while an injection of IFN alone of this dose did not change its activities (n = 10). HCV RNA levels were significantly decreased by IFN only after the administration of the preparation (intramuscular, p < 0.01; intravenous, p < 0.01). The effect of intravenous injection of this preparation was also elicited in patients with HCV genotype D and with HCV more than 105 copies/ml. These results suggest that this preparation may enhance the 2'5-AS production by IFN as a result of the increase in mitochondrial adenosin triphosphate production and may be a potent agent to enhance the anti-viral efficacy of IFN in patients with CH-C.

KW - chronic hepatitis C

KW - flavin adenin dinucleotide

KW - interferon

KW - liver extract

UR - http://www.scopus.com/inward/record.url?scp=0029986496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029986496&partnerID=8YFLogxK

M3 - Article

C2 - 8882468

AN - SCOPUS:0029986496

VL - 45

SP - 48

EP - 53

JO - Keio Journal of Medicine

JF - Keio Journal of Medicine

SN - 0022-9717

IS - 1

ER -